Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediacel versus Infanrix-IPV+Hib in infants on the Nordic 3-5-12 month schedule
2005-004133-17Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diphtheria, Tetanus, pertussis and 2 more comparing Pediacel with Infanrix-IPV+Hib (2 arms). Primary endpoint: Seroprotective antibody response 1 month after dose 3. Started Oct 2005; status: completed.
02
Drugs
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccineInfanrix-IPV + Hib
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2005-004133-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004133-17.